48th week of 2013 patent applcation highlights part 38 |
Patent application number | Title | Published |
20130315853 | COSMETIC COMPOSITION COMPRISING A CUCURBIC ACID COMPOUND AND AN ACRYLIC COPOLYMER - The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a cucurbic acid compound of formula (I) in which R | 2013-11-28 |
20130315854 | Composition For Soft Tissue Treatment - A composition for use in treating soft tissue in a living creature with a bulking material prepared in situ from a composition of an addition curable polysiloxane system. | 2013-11-28 |
20130315855 | Repellent Coating Composition and Coating, Method for Making and Uses Thereof - A cross-linkable coating composition comprises (i) one or more silanes having either at least three hydrolysable groups, or at least two hydrolysable groups and at least one organofunctional group capable of forming chemical bonds upon curing, wherein (i.a) the sum of said silanes constitutes at least 20% of the total mass of the coating compositions combined solids and silanes, and (i.b) said silanes are possibly partly or completely hydrolysed and possibly partly condensed, and (ii) at least one low surface energy additive, wherein (ii.a) said low surface energy additive comprises polydimethylsiloxane chemically bonded to at least one functional group, (ii.b) said functional group is configured for the polydimethylsiloxane moiety to cross-link with said coating composition, (ii.c) said polydimethylsiloxane constitutes 0.01% to 15% of the mass of said cured coating, when said coating composition is cured, and (ii.d) said polydimethylsiloxane moiety has a molecular weight of more than 1600 g/mol. | 2013-11-28 |
20130315856 | CONJUGATES FOR THE TREATMENT OF MESOTHELIOMA - The present invention provides conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers. | 2013-11-28 |
20130315857 | Kexin-Derived Vaccines to Prevent or Treat Fungal Infections - A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as | 2013-11-28 |
20130315858 | Common and Rare Genetic Variations Associated with Common Variable Immunodeficiency (CVID) and Methods of Use Thereof for the Treatment and Diagnosis of the Same - Compositions and methods useful for the diagnosis and treatment of common variable immunodeficiency are disclosed. | 2013-11-28 |
20130315859 | ANTI-INFLAMMATORY COMPOSITIONS - Provided herein are methods for the treatment of abnormal inflammation and inflammatory conditions comprising mucosal administration of an effective amount of an interleukin (e.g. IL-2) or a fragment or derivative thereof. Also provided herein are pharmaceutical compositions for mucosal administration for the treatment of abnormal inflammation and inflammatory conditions, the composition comprising said interleukin or fragment or derivative. | 2013-11-28 |
20130315860 | METHODS AND COMPOSITIONS BASED ON DIPHTHERIA TOXIN-INTERLEUKIN-3 CONJUGATES - The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells. In other embodiments, the methods of the present invention relate to ex vivo purging of bone marrow or peripheral blood to remove cells that express one or more subunits of the interleukin-3 receptor such that the purged bone marrow or peripheral blood is suitable, e.g., for autologous stem cell transplantation to restore hematopoietic function. | 2013-11-28 |
20130315861 | INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2013-11-28 |
20130315862 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS - A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. | 2013-11-28 |
20130315863 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE INFECTIONS - A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. | 2013-11-28 |
20130315864 | MACROCYCLIC NUCLEOSIDE PHOSPHORAMIDATE DERIVATIVES - The present invention provides nucleoside phosphoramidate compounds of Formula I, | 2013-11-28 |
20130315865 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS - Compounds of formula I | 2013-11-28 |
20130315866 | 3',5'-CYCLIC PHOSPHORAMIDATE PRODRUGS FOR HCV INFECTION - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2013-11-28 |
20130315867 | 3',5'-CYCLIC PHOSPHATE PRODRUGS FOR HCV INFECTION - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2013-11-28 |
20130315868 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE - Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2013-11-28 |
20130315869 | BACTERIOPHAGES FOR REDUCING TOXICITY OF BACTERIA - A genetically modified bacteriophage is disclosed which comprises:
| 2013-11-28 |
20130315870 | COMPOSITIONS AND METHODS FOR RETARGETING VIRUS CONSTRUCTS - The present invention relates to the field of viral gene therapy. More specifically, A the present invention provides compositions and methods for retargeting virus constructs. In one embodiment, the present invention provides an adenoviral construct comprising a nucleic acid encoding the peptide sequence MAE-X-PDP, wherein X is an antigen targeting peptide. In a more specific embodiment, an adenoviral construct comprises a nucleic acid sequence encoding the peptide sequence MAEWQPDTAHHWALTLPDP inserted into the HI-loop of adenovirus fiber protein. In yet another embodiment, the present invention provides a method for optimizing adenoviral infection of target cells comprising the steps of (a) generating a peptide-display adenovirus library, wherein the displayed peptide is a peptide that specifically binds an antigen expressed on the surface of a target cell, and wherein the displayed peptide is flanked by random peptide sequences; and (b) screening the peptide-display adenovirus library against the target cells. | 2013-11-28 |
20130315871 | SUBFAMILY E SIMIAN ADENOVIRUSES A1302, A1320, A1331 AND A1337 AND USES THEREOF - Recombinant vectors comprise simian adenovirus A1302 (SAdV-A1302, SAdV-A1320, SAdV-A1331, and/or SAdV-A1337 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1302, SAdV-A1320, SAdV-A1331, and/or SAdV-A1337 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 2013-11-28 |
20130315872 | NEURON-SPECIFIC RETROGRADE TRANSPORT VECTOR - The present invention provides a lentiviral vector system having a higher titer, while sustaining an excellent retrograde transport ability, particularly, in the brain. | 2013-11-28 |
20130315873 | PESTICIDE COMPOSITION FOR SHORTENING THE VIRUS LETHAL TIME - The present invention is related to a pesticide composition for shortening the virus lethal time that comprises 0.01-75% of a ryanodine receptor insecticide or a diamides insecticide and 10 | 2013-11-28 |
20130315874 | INHIBITION AND DISPERSION OF BIOFILMS IN PLANTS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES - Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an active compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator. | 2013-11-28 |
20130315875 | AMNION DERIVED ADHERENT CELLS - Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals. | 2013-11-28 |
20130315876 | DIFFERENTIATION OF HUMAN EMBRYONIC AND INDUCED PLURIPOTENT STEM CELLS - The invention relates to culture systems, methods, and conditions that allow pluripotent undifferentiated hESCs or iPSCs to progressively and uniformly differentiate into cells of the chondrogenic lineage. | 2013-11-28 |
20130315877 | ANTICANCER COMPOSITION COMPRISING PLANT STEM CELL LINE DERIVED FROM TAXUS CAMBIUM OR PROCAMBIUM - The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a | 2013-11-28 |
20130315878 | Methods and Compositions Comprising Hyaluronan for Enhancing Bone Marrow Cell Therapy - Disclosed herein are methods and compositions for treating cardiovascular disease and damaged cardiac tissue which employ at least one hyaluronan (HA) compound and one or more cells selected from the group consisting of stem cells, precursor cells, progenitor cells, committed cells, mature somatic cells, and recombinant cells. | 2013-11-28 |
20130315879 | METHOD FOR EXPANSION OF STEM CELLS AND THE USE OF SUCH CELLS - The present invention demonstrates that SALL4A and SALL4B are strong positive regulators of hematopoetic stem cell expansion. HSCs receiving expression of SALL4A or SALL4B are able to achieve a high-level of expansion. Cultures of SALL4-transduced cells results in extensive HSC expansion with over 1000-fold higher levels than controls within 2 to 3 weeks and expanded HSCs show no or very little maturation. Moreover, the expansion occurs quite rapidly with significant HSC growth in just a few days. In addition, SALL4-induced HSC expansion exhibits no impairment of hematopoietic cell differentiation. SALL4 appears to function in the maintenance of an undifferentiated proliferation state and block cell differentiation for HSCs. | 2013-11-28 |
20130315880 | ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS - The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. | 2013-11-28 |
20130315881 | METHOD AND ASSAY FOR GLYCOSYLATION PATTERN DETECTION RELATED TO CELL STATE OF STEM CELLS - A method and assay for characterizing populations of stem cells according to their glycosylation pattern, particularly for distinguishing between stem cell populations, for example with regard to state of differentiation. | 2013-11-28 |
20130315882 | Stem Cell Aggregates and Methods for Making and Using - The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, undo dermal, and mesodermal embryonic germ layers, e.g., stem cells. | 2013-11-28 |
20130315883 | CONTROL OF PATHOGENS AND PARASITES - The present invention relates to the genetic control of parasites and pathogens via the expression of silencing RNA in transgenic plants, including microalgae. In one aspect, the invention exploits the ability of plants to express the silencing RNA in a form within chloroplasts that is efficiently taken up, after ingestion where it can act to suppress the expression of target genes within the pathogen or parasite. | 2013-11-28 |
20130315884 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY - Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections. | 2013-11-28 |
20130315885 | INTEROGATORY CELL-BASED ASSAYS FOR IDENTIFYING DRUG-INDUCED TOXICITY MARKERS - Described herein is a discovery Platform Technology for analyzing a drug-induced toxicity condition, such as cardiotoxicity via model building. | 2013-11-28 |
20130315886 | RETROELEMENTS AND MENTAL DISORDERS AND METHODS OF MEASURING L1 RETROTRANSPOSITION - A method of treating increased non-LTR retrotransposition in a cell. The method includes exposing a neural cell to a retrotransposition inhibitor in an amount sufficient to decrease the non-LTR retrotransposition in the neural cell or a progeny of the neural cell. In various embodiments, the non-LTR retrotransposition involves at least one L1 retrotransposon. Also provided is a method of assaying retrotransposition in neural cells. The method includes sorting synchronized neural cells of the same genetic background into single neural cells, and subjecting one or more of the sorted single neural cells to quantitative polymerase chain reaction amplification of at least one retrotransposon. In addition, a method of identifying an inhibitor of retrotransposition and a identifying a neural condition associated with non-LTR retrotransposition are provided. | 2013-11-28 |
20130315887 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF SERYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-11-28 |
20130315888 | CARRIER FOR TARGETING NERVE CELLS - The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by | 2013-11-28 |
20130315889 | CARTILAGE OLIGOMERIC MATRIX PROTEIN (COMP)-GROWTH FACTOR COMPLEXES AND USES THEREOF - The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenesis, and repair of cartilage and bone lesions. | 2013-11-28 |
20130315890 | Extramuscular treatment of traumatic-induced migraine headache - A method for selection and treatment of externally caused migraine headache, the method includes identifying a patient group having chronic migraine headache; determining the identified patient group, a specific patient with a post traumatic migraine headache; and administering to the selected patient by injection of a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the selected patient's head or upper neck; administration preferably being on the sites of the trigeminal cervical system, enabling axonal transport of the neurotoxin from distal to central sites; and the administration preferably comprising extramuscular injection of the neurotoxin of suitable dilution (a) over the aponeurotic fascia to enable the neurotoxin to diffuse into distal sensory nerves, in order to concentrate the neurotoxin over the occipital-parietal-frontal head region, or (b) intra-orally, in a foramina of the sphenopalatine ganglion for enabling diffusion of the neurotoxin to the ganglion, or (c) to emerging exit points of nerves including foraminal sites for enabling the neurotoxin access to concentrated nerve bundles at exit points of the foramina. | 2013-11-28 |
20130315891 | FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODS - Provided are high concentration compositions of tissue kallikrein-1 (KLK1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human KLK1 (rhKLK1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof. | 2013-11-28 |
20130315892 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS TARGETING 4IG-B7-H3 AND ITS COUNTERPART NK CELL RECEPTOR - The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein. | 2013-11-28 |
20130315893 | HUMANIZED ANTI-IL-20 ANTIBODY AND USES THEREOF - The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure. | 2013-11-28 |
20130315894 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 2013-11-28 |
20130315895 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET - Methods for treating a disease state for which HGF/cMET possesses activity that contributes to the pathology and/or symptomology of the disease state, as well as kits and articles of manufacture for use in practicing these methods. | 2013-11-28 |
20130315896 | Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention. | 2013-11-28 |
20130315897 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor - The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof. | 2013-11-28 |
20130315898 | BIOMARKERS FOR ASTHMA - The present invention provides methods, kits, and compositions related to testing a sample for the level of a biomarker related to asthma, wherein the biomarker is selected from: taurine, maltose, maltotriose, adenosine 5′-monophosphate, phosphoethanolamine, glycerophosphorylcholine, arachidonate, heptanoate, pelargonate, and nicotinamide. In certain embodiments, the level of the biomarker is used to identify therapy effective for treating asthma. In other embodiments, the level of the biomarker is used to identify the presence, severity, or risk of exacerbation of asthma. In further embodiments, the level of the biomarker is used to monitor the response to on-going therapy (e.g., adjust the dosage of the asthma therapy). | 2013-11-28 |
20130315899 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer. | 2013-11-28 |
20130315900 | HUMANIZED ANTI-CD40 ANTIBODIES CONJUGATED TO THERAPEUTIC AGENTS - Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen. | 2013-11-28 |
20130315901 | NOVEL USES - A method of treating, arresting or preventing a disease responsive to treatment with an anti-CD20 antibody in a patient suffering therefrom, comprising administering to the patient at least one sub-depleting dose of antiCD20 antibody is disclosed. | 2013-11-28 |
20130315902 | ANTITUMOR PEPTIDE DERIVED FROM A COMPLEMENTARITY DETERMINING REGION OF A HUMANIZED MONOCLONAL ANTIBODY TO NAP12B TRANSPORTER - Described herein is novel isolated or synthetic peptides derived from a complementarity determining region hypervariable domain amino acid sequence of a humanized monoclonal antibody to NaPi2B transporter, as well as derivatives thereof, and a pharmaceutical composition and a method for inhibiting tumor growth or treating a tumor or cancer treating using the antitumor peptides and derivatives thereof. | 2013-11-28 |
20130315903 | ARYLSULFONAMIDE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF SPECIFIC OPHTHALMOLOGIC DISORDERS - The invention is directed to the therapeutic use of arylsulfonamide derivatives. | 2013-11-28 |
20130315904 | COMBINATIONS OF MODALITIES FOR THE TREATMENT OF DIABETES - A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith. | 2013-11-28 |
20130315905 | B7-H5, A Costimulatory Polypeptide - B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein. | 2013-11-28 |
20130315906 | Activatable Antibodies That Bind Epidermal Growth Factor Receptor And Methods Of Use Thereof - The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications. | 2013-11-28 |
20130315907 | VEGF-A121 ASSAY - The invention provides a method for determining the level of VEGF-A | 2013-11-28 |
20130315908 | METHOD FOR TREATMENT OF ANEURYSMS - The present invention generally concerns the detection and/or treatment of aneurysm in a non-invasive manner. In particular cases, the invention concerns methods and compositions for localizing a labeled composition to the site of an aneurysm for its detection and, in further cases, treatment of the aneurysm. In specific cases, the composition targets a subendothelial component of the aneurysmal wall, such as a smooth muscle cell exposed at the luminal surface of the vessel. In further specific cases, the composition targets an integrin receptor or laminin. | 2013-11-28 |
20130315909 | CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, METHOD OF MAKING AND USE THEREOF - This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival. | 2013-11-28 |
20130315910 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 2013-11-28 |
20130315911 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 2013-11-28 |
20130315912 | Antibodies that Bind to Adrenomedullin and to Adrenomedullin Receptors and the Uses Thereof as Drugs - The invention relates to antibodies that bind to adrenomedullin and to proteins forming adrenomedullin receptors and to the uses thereof as drugs. | 2013-11-28 |
20130315913 | ANTI-LIGHT ANTIBODY THERAPY FOR INFLAMMATORY BOWEL DISEASE - The present invention provides safe therapeutic doses of an antagonist of human LIGHT (lymphotoxin-like, exhibits inducible expression and competes with Herpes Virus Glycoprotein D for Herpes Virus Entry Mediator (HVEM), a receptor expressed by T lymphocytes), as well as methods of monitoring whether a therapeutic dose of an anti-LIGHT antagonist is safe. | 2013-11-28 |
20130315914 | Anti-TLR4 Antibodies and Uses Thereof - Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents. | 2013-11-28 |
20130315915 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING DISEASES - Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods. | 2013-11-28 |
20130315916 | RESPIRATORY SYNCYTIAL VIRUS VACCINE - Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject. | 2013-11-28 |
20130315917 | ANITBODIES SPECIFIC FOR THE PROTOFIBRIL FORM OF BETA-AMYLOID PROTEIN - Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human β-amyloid peptide as compare to low molecular weight forms of β-amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment of Alzheimer's disease by effectively blocking the ability of the protofibril form of β-amyloid peptide to form fibril forms linked with complications associated with Alzheimer's disease. The isolated antibodies of the present invention are also useful in various diagnostic assays and associated kits. | 2013-11-28 |
20130315918 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 2013-11-28 |
20130315919 | ANTI-IL-22RA ANTIBODIES - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners. | 2013-11-28 |
20130315920 | Cross Protective Epitopes of Aspergillus Fumigatus and Candida Albicans - A complex comprising a Class II HLA-DRB1*03 or Class II HLA-DRB1*13 molecule bound to a peptide, wherein the peptide comprises the amino acid sequence HTYTIDWTKDAVTWS or a portion thereof, or a variant of the given amino acid sequence or portion wherein the side chains of one or two or three or four or five or six or seven of the amino acid residues are altered, wherein the peptide comprising the portion, or variant, is capable of binding HLA-DRB1*03 and/or HLA-DRB1*13. The complex may be used to select | 2013-11-28 |
20130315921 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR CD22 - Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (K | 2013-11-28 |
20130315922 | METHOD FOR INDUCING LYMPHOID TISSUE AND MODULATING INTESTINAL HOMEOSTASIS - Methods and products for modulating the lymphoid system, especially intestinal homeostasis between intestinal lymphoid tissues and gut flora using ligands for NOD1 and/or CCR6. | 2013-11-28 |
20130315923 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS - Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding | 2013-11-28 |
20130315924 | Subdermal Tissue Remodeling Using Myostatin, Methods and Related Systems - Systems and methods of tissue remodeling or altering a surface of a skin of a patient are provided. A method includes increasing myostatin activity in a target tissue. Methods can include increasing myostatin activity in a target tissue in addition to various tissue remodeling techniques, including cryogenic cooling of target tissue for tissue remodeling. | 2013-11-28 |
20130315925 | METHOD FOR TREATING AND PREVENTING TYPE 2 DIABETES - Methods and compositions for treating or preventing type 2 diabetes by inhibiting expression or activity of monoacylglycerol O-acyltransferase 1 (MOGAT1) are disclosed. Also disclosed are methods to identify such compositions. | 2013-11-28 |
20130315926 | METHODS AND MATERIALS FOR MODULATING RESISTANCE TO APOPTOSIS - This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided. | 2013-11-28 |
20130315927 | PCSK9 ANTAGONISTS - The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies. | 2013-11-28 |
20130315928 | LUTEINIZING-HORMONE LIGAND AND LIGAND-GONADOTROPHIN COMPLEX - The invention relates to a ligand of a luteinizing hormone (LH), characterized in that it comprises the paratope of an ovine anti-LH antibody of which the variable domain of the heavy chain contains the following CDRs: —VH-CDR1, defined by the sequence GYTFTNYW (SEQ ID NO: 13); —VH-CDR2, defined by the sequence IYPGGGYT (SEQ ID NO: 14); —VH-CDR3, defined by the sequence ARTPLYGSSYGGFAY (SEQ ID NO: 15); and the variable domain of the light chain contains the following CDRs: —VL-CDR1, defined by the sequence QGISNY (SEQ ID NO: 16); —VL-CDR2, defined by the sequence YTS; —VL-CDR3, defined by the sequence QQYSKLPWT (SEQ ID NO: 17). The invention also relates to a ligand-gonadotrophin (LH, hCG, FSH) complex. The ligand or the complex according to the invention can be used to induce ovulation in a female mammal. | 2013-11-28 |
20130315929 | VACCINE ANTIGENS THAT DIRECT IMMUNITY TO CONSERVED EPITOPES - A method of identification and elimination of immunodominant epitopes to elicit a response to secondary epitopes, especially conserved structures, is described, and applied to influenza haemagglutinin (HA). Identification of the primary epitopes in (HA), and replacement of amino acids having high LODrps with corresponding low LODrps amino acids produces an HA molecule which induces antibody responses to conserved HA residues. Modified HA molecules induce a broadly neutralizing vaccine. | 2013-11-28 |
20130315930 | GENETIC AMPLIFICATION OF IQGAPI IN CANCER - We examined IQGAP1 copy gain and its relationship with clinicopathologic outcomes of thyroid cancer and investigated its role in cell invasion and molecules involved in the process. We found IQGAP1 copy number (CN) gain ?3 in 1 of 30 (3%) of benign thyroid tumor, 24 of 74 (32%) follicular variant papillary thyroid cancer (FVPTC), 44 of 107 (41%) follicular thyroid cancer (FTC) 8 of 16 (50%) tall cell papillary thyroid cancer (PTC), and 27 of 41 (66%) anaplastic thyroid cancer, in increasing order of invasiveness of these tumors. A similar tumor distribution trend of CN ?4 was also seen. IQGAP1 copy gain was positively correlated with IQGAP1 protein expression. It was significantly associated with extrathyroidal and vascular invasion of FVPTC and FTC and, remarkably, a 50%-60% rate of multifocality and recurrence of BRAF mutation-positive PTC (P=0.01 and 0.02, respectively). The siRNA knock-down of IQGAP1 dramatically inhibited thyroid cancer cell invasion and colony formation. Co-immunoprecipitation assay showed direct interaction of IQGAP1 with E-cadherin, a known invasion-suppressing molecule, which was upregulated when IQGAP1 was knocked down. IQGAP1, through genetic copy gain, plays an important role in the invasiveness of thyroid cancer and represents a useful prognostic marker and therapeutic target for this and other cancers. | 2013-11-28 |
20130315931 | CXCR4 as a Susceptibility Locus in Juvenile Idiopathic Arthritis (JIA) and Methods of Use Thereof for the Treatment and Diagnosis of the Same - Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed. | 2013-11-28 |
20130315932 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE - The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure. | 2013-11-28 |
20130315933 | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy - Specific binding members, particularly antibodies and fragments thereof, which bind to HLA-B27 heavy-chain homodimers, termed HC-B27, HLA-B27 | 2013-11-28 |
20130315934 | Methods and Compositions for Assessing and Treating Cancer - The invention relates to methods and compositions for identifying mutations associated with cancer, such as melanoma. More particularly, the invention relates to methods and compositions for assessing particular mutations as markers for cancer, such as melanoma. Such methods and compositions allow medical providers to diagnose cancer, such as melanoma, based upon the presence of one or more particular mutations in a subject, as compared with an otherwise healthy control. The methods and compositions are also useful in guiding the type of therapy to be applied, and monitoring the effects of the therapy applied. | 2013-11-28 |
20130315935 | OLIGOMERIC RECEPTOR LIGAND PAIR MEMBER COMPLEXES - This invention concerns an oligomeric receptor-ligand pair member in general and an oligomeric MHC-peptide complex in particular and a method of labeling, detecting and separating mammalian T cells according to the specificity of their antigen receptor by use of the oligomer. The invention further concerns a method of targeting the oligomeric receptor-ligand pair member complexes to target molecules of the surface of a target cell in order to present antigens on the target cell. The invention further concerns related pharmaceutical and diagnostic compositions and processes. | 2013-11-28 |
20130315936 | METHOD FOR NON-INVASIVE TREATMENT OF CEREBRAL ANEURYSMS - Described herein is a method for non-invasive detection and treatment of intra-cranial aneurysms. Antibodies are provided to specifically react/bind with antigens of the cerebral aneurism wall. The antibodies may be bound to a label and/or to a therapeutic agent for diagnosis and/or for treatment purposes thereof. Intra-cranial aneurysms are thus non-invasively detected before rupture occurs and are specifically treated. | 2013-11-28 |
20130315937 | LIPID NANOPARTICLE COMPOSITIONS FOR ANTISENSE OLIGONUCLEOTIDES DELIVERY - Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed. | 2013-11-28 |
20130315938 | Delivering polypeptides to phagocytes - The current invention is a particle comprising an assembly of lipid-enveloped core polypeptides and transmembrane polypeptides. The transmembrane polypeptides comprise sequences that bind to phagocytes through indirect or direct binding by surface receptors. The result of transmembrane polypeptide binding is engulfment by the phagocyte to low-pH compartments. The low pH triggers a conformational change in transmembrane polypeptides whereby lipids of particles and phagocytes are fused and the contents of the particle, including a polypeptide to be delivered to the cell, are released into the phagocyte. | 2013-11-28 |
20130315939 | Use of Cytokines and Mitogens to Inhibit Pathological Immune Responses - The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders. | 2013-11-28 |
20130315940 | TREATMENT OF LIVER CANCER - The present invention derives from the finding that increased levels of Toll related receptor 9 (TLR9) and Toll related receptor 7 (TLR7) are associated with liver cancer and in particular hepatocellular carcinoma. Accordingly, the invention provides TLR9 and TLR7 antagonists for use in a method of treating liver cancer. The invention provides other strategies such as modulation of endosomal signalling by using compounds such as chloroquine to prevent or treat such liver cancer. The invention also provides agents capable of inducing an immune response against TLR9 and TLR7 for use in a method of treating liver cancer. The presence of TLR9 and TLR7 expression may be indicative of the presence of liver cancer and the amount of TLR9 and TLR7 expression may be indicative of the rate of growth or spreading of the cancer. | 2013-11-28 |
20130315941 | YEAST-MUC1 IMMUNOTHERAPEUTIC COMPOSITIONS AND USES THEREOF - Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1). | 2013-11-28 |
20130315942 | WDRPUH Epitope Peptides and Vaccines Containing the Same - The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines. | 2013-11-28 |
20130315943 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 58 - Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection. | 2013-11-28 |
20130315944 | INFECTIOUS GENOMIC DNA CLONE AND SEROLOGICAL PROFILE OF TORQUE TENO SUS VIRUS 1 AND 2 - The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of | 2013-11-28 |
20130315945 | YEAST-BASED VACCINES AS IMMUNOTHERAPY - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 2013-11-28 |
20130315946 | VACCINE COMPOSITION AGAINST STREPTOCOCCUS PYOGENES INFECTION - The present invention relates to a vaccine composition against | 2013-11-28 |
20130315947 | Vaccination of Animals to Elicit a Protective Immune Response Against Tick Infestations and Tick-Borne Pathogen Transmission - Two antigenic and immunogenic proteins of the cattle tick, | 2013-11-28 |
20130315948 | CONTROLLED RELEASE FORMULATION BASED ON HEMATIN ANHYDRIDE CRYSTALS FOR THE INDUCTION OF AN INNATE IMMUNE REACTION - The present invention relates to a new process for producing a doped synthetic monodispersed hematin anhydride (HA) crystals useful as a slow release vehicle and immune modulator. As the preparation comprises embedded in the crystals one or more antigens and/or one or more biologically active entities, the preparation can be useful in numerous medical indications such as vaccine or any therapy where it is desired that a biologically active entity maintains its activity over time due to its slow-release. The process comprises the steps of (i) providing a substantially pure iron(III) protoporphyrin-IX, in solution in an alkaline solution substantially free of oxygen (ii) adjusting the pH of the solution to an acidic pH of between about 4.0, by slowly adding a medium strong organic acid, (iii) during step b) above, adding one or more antigens and/or one or entities having a biological activity, at a pH of about 5.0. | 2013-11-28 |
20130315949 | Molecular Antigen Array - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses. | 2013-11-28 |
20130315950 | METHODS AND COMPOSITIONS USING LISTERIA FOR ADJUVANT TREATMENT OF CANCER - Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active | 2013-11-28 |
20130315951 | COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE AGAINST INFECTIOUS AGENTS - The invention provides for oral compositions for safely stimulating an immune response to mucoadhesive antigens for protection against infectious agents, particularly influenza viruses using heat-labile, mutant | 2013-11-28 |
20130315952 | ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION - The invention provides compositions and methods for the prophylaxis or treatment of diseases or disorders in a subject (e.g., a mammal, such as a human) including, e.g., diseases or disorders caused by biological agents, autoimmune diseases, and cancer. The compositions include a delivery vector (e.g., a viral vector, such as an Ad5 vector) encoding an interferon (e.g., IFN-α), and are provided to the subject by, e.g., intranasal or pulmonary administration. | 2013-11-28 |